Ampio Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides Business Update
Ampio Pharmaceuticals (AMPE) reported its financial results for Q3 and YTD 2021 on November 10, showing a net loss of $3.6 million for Q3, an 8% increase from the previous year, with diluted net loss per share remaining unchanged at $0.02. Operating expenses rose by 17% to $3.85 million, driven mainly by a 57% increase in R&D expenditures. Cash and cash equivalents decreased slightly to $17.1 million, with guidance indicating sufficient funds to operate through Q1 2023. The company is advancing its Ampion therapy in both clinical and preclinical studies, including a Phase 2 COVID-19 trial in India.
- Advancement of Ampion therapy in clinical and preclinical studies.
- Initiated Phase 2 AP-019 study for COVID-19 in India.
- R&D expenses increased primarily due to ongoing studies, indicating active development.
- Net loss increased by 8% year-over-year for Q3.
- Operating expenses rose by 17%, impacting financial performance.
ENGLEWOOD, Colo., Nov. 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, today reported results for the three- and nine-month periods ended September 30, 2021 and provided a corporate overview and business update.
Ms. Holli Cherevka, President and Chief Operating Officer, commented, "This quarter marked an exciting period of growth for drug development in the Ampion platform therapy, both in clinical and preclinical development.
We have locked the osteoarthritis Phase 3 pivotal trial database, and are currently analyzing the data, which may provide a significant treatment option for an unmet medical need in severely disabled patients.
We have commenced the enrollment and treatment of COVID-19 patients in India for the Phase 2 AP-019 study utilizing inhaled Ampion therapy compared to control.
Furthermore, we continue to investigate Ampion's potential in new indications within the preclinical space, most recently publishing data supportive of application in acute kidney injury, and in the autoimmune space relating to lupus nephritis. This early data suggests we may still be just scratching the surface of Ampion's potential."
Ms. Holli Cherevka, President and Chief Operating Officer, Howard Levy, M.B.B.Ch., Ph.D., M.M.M., Chief Medical Officer, David Bar-Or, MD, Director and Founder, and Mr. Daniel Stokely, Chief Financial Officer will be hosting a Conference Call for the Investment Community this afternoon beginning at 4:30 PM ET (see details below).
The key areas of focus during the call will be clinical and preclinical updates, as well as the financial results for the three and nine-month period ended September 30, 2021.
SEPTEMBER 30, 2021 FINANCIAL RESULTS
Cash and cash equivalents totaled
QTD | YTD | |||||
Description | 2021 | 2020 | % Change | 2021 | 2020 | % Change |
Operating Expenses | $ 3,851,000 | $ 3,302,000 | $ 11,343,000 | $ 11,923,000 | - | |
Net Loss | $ 3,628,000 | $ 3,368,000 | $ 10,851,000 | $ 11,277,000 | - | |
Net Loss per share | $ 0.02 | $ 0.02 | $ 0.06 | $ 0.07 | - | |
Operating Expenses: Operating expenses consist of research and development ("R&D") expenses and general and administrative ("G&A") expenses, both of which are further explained below.
QTD | YTD | |||||
Description | 2021 | 2020 | % Change | 2021 | 2020 | % Change |
R&D | $ 2,594,000 | $ 1,655,000 | $ 7,163,000 | $ 7,027,000 | ||
G&A | $ 1,257,000 | $ 1,647,000 | - | $ 4,180,000 | $ 4,896,000 | - |
Total Operating Expenses | $ 3,851,000 | $ 3,302,000 | $ 11,343,000 | $ 11,923,000 | - | |
Research and Development Expenses: R&D expenses for the three months ended September 30, 2021 increased by
R&D expenses for the nine months ended September 30, 2021 increased by
General and Administrative Expenses: G&A expenses for the three months ended September 30, 2021, decreased by approximately
The total shares of common stock outstanding were 200,458,263 on September 30, 2021, compared to 193,378,996 on December 31, 2020.
Financial Guidance
Based on its current projection and expected access to equity financing, Ampio expects to have cash and cash equivalents along with access to external sources of liquidity sufficient to fund its business operations through the first quarter of 2023.
Conference Call & Webcast:
Wednesday, November 10, 2021, 4:30 pm EDT / 2:30 pm MT
Webcast Link: https://event.on24.com/wcc/r/3499388/60A0DA16A47D6B146B1AA111CA73357E
Conference Call (listen only): Canada dial-in number (Toll Free): 1 833 950 0062
Canada dial-in number (Local): 1 226 828 7575
United States: 1 844 200 6205
United States (Local): 1 646 904 5544
All other locations: +1 929 526 1599
Access code: 385971
In order to submit questions, participants must have internet connectivity, as questions will only be addressed via the webcast. The conference call line will be in listen only mode.
The conference call and webcast can also be accessed from the Investor Relations section of the Company's website at www.ampiopharma.com and will be archived there shortly after the live event.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat common inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "could," "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's ability to access equity financing and fund research and development programs and operations through the fourth quarter of 2022, expectations with respect to Ampion, including its ability to treat common inflammatory conditions for which there are limited treatment options (including COVID-19) and its ability to offer the benefits of steroids without the side effects, the significance of reported results from early clinical trials, the timing of patient enrollment for the Phase I Long-COVID trial and the Phase II COVID-19 trials, the timing and outcome of the Company's application for Emergency Use Authorization of Ampion in COVID-19 patients with inhalation and intravenous routes of drug delivery, the term of Ampion's patent protection and the timing and likelihood of Ampion's approval as a novel biologic under the BPCIA, including the availability of 12-year FDA market exclusivity in connection with such approval. These forward-looking statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Ampio and are subject to significant risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, in Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
AMPIO PHARMACEUTICALS, INC. Condensed Balance Sheets (unaudited) | ||||||
September 30, | December 31, | |||||
2021 | 2020 | |||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | $ | 17,118,000 | $ | 17,346,000 | ||
Prepaid expenses and other | 1,850,000 | 1,147,000 | ||||
Total current assets | 18,968,000 | 18,493,000 | ||||
Fixed assets, net | 2,827,000 | 3,561,000 | ||||
Right-of-use asset | 679,000 | 824,000 | ||||
Total assets | $ | 22,474,000 | $ | 22,878,000 | ||
Liabilities and Stockholders' Equity | ||||||
Current liabilities | ||||||
Accounts payable and accrued expenses | $ | 2,083,000 | $ | 1,550,000 | ||
Lease liability-current portion | 304,000 | 284,000 | ||||
Total current liabilities | 2,387,000 | 1,834,000 | ||||
Lease liability-long-term | 694,000 | 925,000 | ||||
Warrant derivative liability | 2,118,000 | 2,607,000 | ||||
Total liabilities | 5,199,000 | 5,366,000 | ||||
Commitments and contingencies (Note 7) | ||||||
Stockholders' equity | ||||||
Preferred Stock, par value | — | — | ||||
Common Stock, par value | 20,000 | 19,000 | ||||
Additional paid-in capital | 228,633,000 | 218,020,000 | ||||
Accumulated deficit | (211,378,000) | (200,527,000) | ||||
Total stockholders' equity | 17,275,000 | 17,512,000 | ||||
Total liabilities and stockholders' equity | $ | 22,474,000 | $ | 22,878,000 | ||
AMPIO PHARMACEUTICALS, INC. Condensed Statements of Operations (unaudited) | |||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||
Operating expenses | |||||||||||||
Research and development | $ | 2,594,000 | $ | 1,655,000 | $ | 7,163,000 | $ | 7,027,000 | |||||
General and administrative | 1,257,000 | 1,647,000 | 4,180,000 | 4,896,000 | |||||||||
Total operating expenses | 3,851,000 | 3,302,000 | 11,343,000 | 11,923,000 | |||||||||
Other income (expense) | |||||||||||||
Interest income | 1,000 | — | 3,000 | 12,000 | |||||||||
Paycheck Protection Program loan forgiveness | — | — | — | 544,000 | |||||||||
Derivative gain | 222,000 | 7,000 | 489,000 | 163,000 | |||||||||
Loss on disposal of fixed asset | — | (73,000) | — | (73,000) | |||||||||
Total other income (expense) | 223,000 | (66,000) | 492,000 | 646,000 | |||||||||
Net loss | $ | (3,628,000) | $ | (3,368,000) | $ | (10,851,000) | $ | (11,277,000) | |||||
Net loss per common share: | |||||||||||||
Basic | $ | (0.02) | $ | (0.02) | $ | (0.05) | $ | (0.07) | |||||
Diluted | $ | (0.02) | $ | (0.02) | $ | (0.06) | $ | (0.07) | |||||
Weighted average number of common shares outstanding: | |||||||||||||
Basic | 200,419,371 | 178,622,349 | 197,347,030 | 168,061,672 | |||||||||
Diluted | 201,563,122 | 178,622,349 | 198,576,052 | 168,551,972 | |||||||||
Company Contacts
Investor Relations
Daniel G Stokely, CPA
dstokely@ampiopharma.com
(720) 437-6500
View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-announces-third-quarter-2021-financial-results-and-provides-business-update-301421583.html
SOURCE Ampio Pharmaceuticals, Inc.
FAQ
What were Ampio Pharmaceuticals' Q3 2021 financial results?
How much cash did Ampio have as of September 30, 2021?
What is the financial guidance for Ampio Pharmaceuticals?
What clinical trials is Ampio currently conducting?
